Physician profile
Prithvi Sreenivasan
NPI 1750597704
$260.66
in general payments reported to CMS, 2019-2025
11 companies · $48.54 in 2025
The $48.54 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $127 · 2024: $85.50 · 2025: $48.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.70 | 2023-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $48.54 | 2025 | Sucraid |
| Genzyme Corporation | $37.85 | 2023 | |
| Phathom Pharmaceuticals, INC. | $21.47 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $20.24 | 2023 | |
| Capsovision, INC. | $19.31 | 2023 | Capsocam Plus |
| Ardelyx, INC. | $16.05 | 2024 | Ibsrela |
| Janssen Biotech, INC. | $15.02 | 2023 | Stelara |
| Abbvie INC. | $14.48 | 2023 | Rinvoq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prithvi Sreenivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.